|
Sep 23
|
Orgenesis Announces Reverse Stock Split
|
|
May 21
|
Orgenesis Provides Business Update for the First Quarter of 2024
|
|
Apr 15
|
Orgenesis Provides Year End Business Update
|
|
Apr 10
|
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
|
|
Mar 18
|
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
|
|
Mar 13
|
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
|
|
Mar 4
|
Orgenesis Inc. Announces $2.3 Million Private Placement
|
|
Jan 31
|
EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic
|
|
Nov 8
|
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
|
|
Nov 2
|
Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding
|
|
Aug 11
|
Orgenesis Provides Business Update for Second Quarter of 2023
|
|
Aug 10
|
Orgenesis Schedules Second Quarter 2023 Business Update Conference Call
|